Eligibility for the Merkin Prize extends to important, novel technologies that have had demonstrable clinical & real world impact on human health, such as prevention, diagnosis, or treatment, and the individuals and/or teams who were key contributors to its development. Technologies may have been created through work in academia, the commercial sector, or government. Submissions from nominators in any discipline will be considered.
For the purposes of this prize, a technology is defined as an innovation or invention of a method or device, such as a lab technique, a computational method, a medical device, or a diagnostic test. Nominations for basic discoveries, such as biological pathways, or new uses of already invented technology, will not be considered.
Each nomination must specify and demonstrate the technology’s clinical impact — past, present, and projected future. Technologies that are in either pre-clinical or clinical-trial phases of development are not eligible for the prize.